Business Context and Reporting Period
This Form 10-Q was filed by Venus Acquisition Corporation, not Microalgo Inc., for the quarter and six months ended June 30, 2022. Venus is a Cayman Islands blank-check company formed to complete a business combination and is classified as a shell company, smaller reporting company, and emerging growth company. The filing states that the proposed transaction would result in a name change to MicroAlgo Inc.
The company generated no operating revenue. Its activities consisted primarily of maintaining the trust account, evaluating and pursuing a business combination with VIYI Algorithm Inc. (“VIYI”), and incurring formation, public-company, and transaction expenses.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2022 |
|---|---|---|
| Operating expenses | $90,520 | $258,158 |
| Interest income | $66,917 | $70,732 |
| Net loss | $23,603 | $197,426 |
| Operating cash flow | Not separately provided | $(291,191) |
| Net loss per non-redeemable share | $0.02 | $(0.17) |
- At June 30, 2022, total assets were $47.35 million, including $47.31 million held in the trust account and $10,899 of cash outside the trust account.
- Current liabilities were $1.48 million, including $643,421 of working-capital loans from a related party and $766,665 of related-party extension notes.
- Total liabilities were $3.05 million, including $420,000 of warrant liabilities and $1.15 million of deferred underwriting compensation.
- Working capital deficit was $1.44 million. Shareholders’ deficit was $3.01 million.
- There were 4.6 million ordinary shares subject to possible redemption, recorded as temporary equity at $47.31 million, and 1.45 million non-redeemable ordinary shares outstanding.
- The trust account increased from $46.47 million at December 31, 2021 to $47.31 million at June 30, 2022, primarily from interest income and extension funding.
Material Changes Versus the Prior Comparable Period
- Three-month net loss declined to $23,603 from the filing’s 2021 comparable loss of $218,140, primarily because interest income increased to $66,917 from $706 and operating expenses decreased to $90,520 from $218,846.
- Six-month net loss declined to $197,426 from $306,463 in the 2021 comparable period. The 2021 figures are identified as restated in the financial statements.
- Six-month operating cash used declined to $291,191 from $374,148.
- Related-party loan balances increased from $373,421 at December 31, 2021 to $643,421 at June 30, 2022. Related-party extension notes increased from zero to $766,665.
- The warrant liability increased from $410,000 to $420,000, generating a $10,000 fair-value expense for the six-month period.
- Management disclosed material weaknesses in internal control over financial reporting related to the accounting classification of warrants and redeemable ordinary shares. Prior financial statements were restated for these matters.
Outlook, Transaction Status, Risks, and Unusual Items
- The company was pursuing a proposed stock-for-stock merger with VIYI, valued at approximately $400 million. VIYI shareholders were expected to receive approximately 39.6 million ordinary shares, representing approximately 85% of the combined company assuming no redemptions and conversion of outstanding rights.
- The merger remained subject to shareholder approvals, required financial statements, governmental approvals, minimum net tangible assets, and other customary closing conditions. The filing does not establish that the transaction would close.
- Subsequent to quarter-end, amendments dated August 2 and August 10, 2022 extended the merger’s outside termination date to November 11, 2022 and modified financial statement delivery requirements.
- The company had extended its business-combination deadline to September 11, 2022 through sponsor-funded loans, with additional extensions potentially available to October 11, 2022. If no combination were completed within the applicable period, the company would redeem public shares and liquidate.
- Management stated that these conditions created substantial doubt about the company’s ability to continue as a going concern if a business combination was not completed by the deadline. The financial statements contain no adjustments for a potential liquidation.
- Public shareholders may redeem shares in connection with the business combination. Public rights and warrants may become worthless if the company liquidates without completing a transaction.
- The sponsor’s extension loans are generally non-interest-bearing and payable upon a business combination; they may be converted into additional private units at the lender’s discretion. The sponsor is not obligated to provide future extension funding.
- The company reported no legal proceedings, no unregistered equity issuances during the quarter, no long-term debt other than related-party financing, and no off-balance-sheet arrangements.
- COVID-19 could adversely affect the company’s financial position, operations, or ability to identify and complete a transaction, although the specific impact was not determinable.
Most Important Facts for Investors to Verify
- Confirm the issuer identity and ticker because the supplied metadata references Microalgo Inc., while the filing registrant is Venus Acquisition Corporation and the proposed post-combination name is MicroAlgo Inc.
- Verify whether the VIYI merger was ultimately approved and completed, including the final merger consideration, shareholder redemptions, financing, and resulting capitalization.
- Verify the applicable business-combination deadline and whether any additional extension loans were funded after June 30, 2022.
- Review the restated financial statements and the remediation status of the material weaknesses involving warrant and redeemable-share classification.
- Assess liquidity outside the trust account, related-party loans, and the consequences for public shareholders if the merger failed and liquidation occurred.
- Confirm the treatment and potential dilution from 4.6 million redeemable shares, approximately 482,500 rights-related shares, public warrants, private warrants, and any converted extension or working-capital loans.